Key facts
- Vanqua Bio’s last known valuation is $270.0M.
- It has raised $149.0M across 2 recorded rounds; the latest was Early Stage VC ($45.0M) in Feb 2024.
- Notable investors include OrbiMed, Osage University Partners, Casdin Capital, Logos Capital, Omega Funds — 12 tracked in total.
- Vanqua Bio has filed 2 Form Ds with the SEC since 2021, most recently Jul 2024 ($45.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Vanqua Bio
Funding rounds
2 roundsAbout Vanqua Bio
Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advancing programs targeting the innate immune system, which can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2019
- Employees
- 34
- Website
- vanquabio.com/
- Ownership
- Privately Held (backing)
Vanqua Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vanqua Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vanqua Bio in its N-PORT filings yet. We sweep new filings monthly.